Putting Fine Particulate Matter and Dementia in the Wider Context of Noncommunicable Disease: Where are We Now and What Should We Do Next: A Systematic Review
Conclusion: The evidence base for PM2.5 as a risk factor for dementia is growing. It is not yet as strong as that for other NCDs. However, varied measurement/methodology hampers clarity across the field. We propose next steps.Neuroepidemiology
DEMENTIA symptoms can be highly debilitating so medical interventions aim to make them more manageable. New research published in the journal Lancet has arrived at a surprising and shocking conclusion: a common antidepressant drug used to treat agitation in people with dementia is no less effective than a placebo and it may even increase the risk of death.
DEMENTIA is set to soar in the coming decades but all hope is not lost. Research increasingly sheds light on the modifiable risk factors, which includes eating an everyday food item that increases your risk by a whopping 44 percent.
Contributors : Yuya Asanomi ; Daichi Shigemizu ; Shintaro Akiyama ; Takashi Sakurai ; Kouichi Ozaki ; Takahiro Ochiya ; Shumpei NiidaSeries Type : Expression profiling by arrayOrganism : Homo sapiensThere are many subtypes of dementia, and identification of diagnostic biomarkers that are minimally-invasive, low-cost, and efficient is desired. Circulating microRNAs (miRNAs) have recently gained attention as easily accessible and non-invasive biomarkers. We conducted a comprehensive miRNA expression analysis of serum samples from 1348 Japanese dementia patients, composed of four subtypes —Alzheimer’s disease (AD)...
Conclusion: The result of this study indicates that the microstate dynamics is disturbed in RBD, which might jeopardize the flexibility and adaptability of the brain. Microstates are potential biomarkers to explore the early electrophysiological abnormality of alpha-synucleinopathy diseases.
Conclusions: Ischaemic stroke survivors exhibit greater neurodegeneration compared to stroke-free controls. Brain atrophy is greater in stroke participants who were cognitively impaired early after their stroke. Early cognitive impairment was associated greater subsequent atrophy, reflecting the combined impacts of stroke and vascular brain burden. Atrophy rates could serve as a useful biomarker for trials testing interventions to reduce post-stroke secondary neurodegeneration.Clinical Trail Registration:http://www.clinicaltrials.gov, identifier: NCT02205424.
Sponsored The ADvance II Study sponsored by Functional Neuromodulation is currently seeking volunteers to participate in a clinical trial for mild Alzheimer’s disease. With a lack of effective long-term treatments, researchers are working hard to find new and better future treatments for patients with Alzheimer’s. Advances in treatment are possible through volunteers participating in clinical research studies like ADvance II. The ADvance II Study is researching the use of a surgically implanted device that delivers mild electrical pulses to specific areas of the brain in people with Alzheimer’s. This deep...
Study tests if western diet contributes to the risk of developing Alzheimer's disease.
Being able to grow small organ-like models of the brain allowed researchers from the University of Cambridge to understand what happens at the earliest stages of disease.
By HANS DUVEFELT I happened to read about the pharmacodynamics of parenteral versus oral furosemide when I came across a unique interaction between this commonest of diuretics and risperidone: Elderly dementia patients on risperidone have twice their expected mortality if also given furosemide. I knew that all atypical antipsychotics can double mortality in elderly dementia patients, but was unaware of the additional risperidone-furosemide risk. Epocrates only has a nonspecific warning to monitor blood pressure when prescribing both drugs. This is only today’s example of an interaction I didn’t ...
Conclusions: As implemented by hospitals, BPCI Model 2 was not associated with adverse effects on patient-reported functional status among beneficiaries who may be vulnerable to reductions in care. Hospitals participating in heart failure, sepsis or pneumonia bundled payment episodes should focus on patient care experience while implementing changes in care delivery.